Successful use of single-pass albumin dialysis in the correction of severe hyperbilirubinemia in a case of acute hepatitis E.
SPAD
acute liver failure
albumin dialysis
hepatitis E virus
hyperbilirubinemia
Journal
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
ISSN: 1744-9987
Titre abrégé: Ther Apher Dial
Pays: Australia
ID NLM: 101181252
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
revised:
30
05
2022
received:
30
08
2021
accepted:
13
07
2022
pubmed:
16
7
2022
medline:
4
3
2023
entrez:
15
7
2022
Statut:
ppublish
Résumé
Acute liver failure (ALF) is a rare syndrome defined by the rapid loss of liver function in the absence of pre-existing liver disease, which may be secondary to hepatitis A virus, hepatitis E virus (HEV), or to drugs in about 50% of cases. Extracorporeal albumin dialysis enables the elimination of albumin-bound toxins that accumulate in liver failure. We report a case of ALF secondary to HEV associated with severe hyperbilirubinemia. Patient was treated with four consecutive sessions of single-pass albumin dialysis (SPAD) carried out setting the following parameters: time: 300 min, Qb: 60 mL/min, Qd: 800-1000 mL/min, dialysate containing 4% albumin, citrate: 3-4 mmol/L. SPAD documented good support of liver function. Bilirubin levels were reduced from 22 to 14 g/dL after four treatments. Pruritus was the first clinical sign of improvement. SPAD system can represent a safe and effective therapeutic option.
Identifiants
pubmed: 35838337
doi: 10.1111/1744-9987.13909
doi:
Substances chimiques
Albumins
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
278-283Informations de copyright
© 2022 International Society for Apheresis and Japanese Society for Apheresis.
Références
Tandon R, Froghi S. Artificial liver support systems. J Gastroenterol Hepatol. 2021;36(5):1164-79.
Weber V, Linsberger I, Hauner M, Leistner A, Leistner A, Falkenhagen D. Neutral styrene divinylbenzene copolymers for adsorption of toxins in liver failure. Biomacromolecules. 2008;9(4):1322-8.
Garcia Martinez JJ, Bendjelid K. Artificial liver support systems: what is new over the last decade? Ann Intensive Care. 2018;8(1):109.
Bernal W, Hyyrylainen A, Gera A, Audimoolam WH, Mcphail MJ, Auzinger G, et al. Lessons from look-back in acute liver failure? A single center experience of 3300 patient. J Hepatol. 2013;59(1):74-80.
Boonsrirat U, Tiranathanagul K, Srisawat N, Susantitaphong P, Komolmit P, Praditpornsilpa K, et al. Effective bilirubin reduction by single-pass albumin dialysis in liver failure. Artif Organs. 2009;33(8):648-53.
Sauer IM, Goetz M, Steffen I, Walter G, Kehr DC, Schwartlander R, et al. In vitro comparison of the molecular adsorbent recirculation system (MARS) and single-pass albumin dialysis (SPAD). Hepatology. 2004;39:1408-14.
Bernal W, Wendon J. Acute liver failure. New Engl J Med. 2013;369(26):2525-34.
Schmuck RB, Nawrot GH, Fikatas P, Reutzel-Selke A, Pratschke J, Sauer IM. Single-pass albumin dialysis-a dose-finding study to define optimal albumin concentration and dialysate flow. Artif Organs. 2017;41(2):153-61.
Ringe H, Varnholt V, Zimmering M, Luck W, Gratopp A, König K, et al. Continuous veno-venous single pass albumin hemodiafiltration in children with acute liver failure. Pediat Crit Care Med. 2011;12(3):257-64.
Benyoub K, Muller M, Bonnet A, Simon R, Gazon M, Duperret S, et al. Amounts of bile acids and bilirubin removed during single-pass albumin dialysis in patients with liver failure. Ther Apher Dial. 2011;15(5):504-6.
Piechota M, Piechota A, Misztal M, Bernas S, Pietraszek-Grzywaczewska I. An evaluation of the usefulness of extracorporeal liver support techniques in patients with severe liver dysfunction. Arch Med Sci. 2019;15(1):99-112.
Karvellas C, Bagshaw S, McDermid R, Stollery D, Bain V, Gibney R. A case-control study of single-pass albumin dialysis for acetaminophen-induced acute liver failure. Blood Purif. 2009;28(3):151-8.
Churchwell MD, Pasko DA, Smoyer WE, Mueller BA. Enhanced clearance of highly protein-bound drugs by albumin-supplemented dialysate during modeled continuous hemodialysis. Nephrol Dial Transplant. 2009;24(1):231-8.
Sponholz C, Matthes K, Rupp D, Backaus W, Klammt S, Karailieva D, et al. Molecular adsorbent recirculating system and single-pass albumin dialysis in liver failure-a prospective, randomised crossover study. Crit Care. 2016;20:2.
Kamar N, Marion O, Abravanel F, Izopet J, Dalton HR. Extrahepatic manifestations of hepatitis E virus. Liver Int. 2016;36:467-72.
Piscitani L, Longo MO, Grabocka X, Silvestri S, Arazzi M, Pezzutto A, et al. Extra-hepatic manifestations associated with hepatitis and virus infection. G Ital Nefrol. 2018;35(2):2018-vol2.
Song J, Xian D, Yang L, Xiong X, Lai R, Zhong J. Pruritus: progress toward pathogenesis and treatment. BioMed Res Int. 2018;2018:9625936.
Fuhrmann V, Drolz A, Trauner M. Extracorporeal artificial liver support systems in the management of intractable cholestatic pruritus. Liver Int. 2011;31(suppl. 3):31-3.
Lieu T, Jayaweera G, Zhao P, Poole DP, Jensen D, Grace M, et al. The bile acid receptor TGR5 activates the TRPA1 channel to induce itch in mice. Gastroenterology. 2014;147(6):1417-28.